Abstract
Microsatellite stable/mismatch repair proficient (MSS/MMRp) stage IV colorectal cancer (CRC) remains an area of high unmet medical need, with the vast majority not responding to anti-PD1 checkpoint inhibitors (CPI). It is believed that a cancer vaccine approach could turn such “cold” tumors into “hot” tumors. ATP128 is a single chimeric fusion protein composed of three elements essential to generate potent antitumoral cellular immunity: a proprietary cell-penetrating peptide (CPP) for antigen delivery, a proprietary Toll-like receptor (TLR)-peptide agonist with self-adjuvant properties and a modulable multi-antigenic domain (Mad), where the Mad for CRC includes3 antigens: carcinoembryonic antigen (CEA), Survivin, Achaete-scute complex homolog 2 (ASCL2).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
